Thus, we also examine the administration of GLP-1 RA and/or SGLT2i, ACEI/ARB, moderate-intensity statins, and aspirin in T2DM patients with established or high risk of ASCVD from 2018 to 2023. Here, GLP1R is linked to atherosclerosis.